Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype

Hepatology

Volumn 49, Issue 4, 2009, Pages 1287-1296

  Perra, Andrea ^a   Kowalik, Marta Anna ^a   Pibiri, Monica ^a   Ledda Columbano, Giovanna M ^a   Columbano, Amedeo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; GC 1; GLUCOSE 6 PHOSPHATASE; GLUTATHIONE TRANSFERASE; LIOTHYRONINE; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG; DIETHYLNITROSAMINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; GENE TARGETING; LIVER CELL; LIVER CELL CARCINOMA; MALE; NONHUMAN; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; RAT; ANIMAL; CELL DIFFERENTIATION; DRUG EFFECT; FISCHER 344 RAT; LIVER TUMOR; METABOLISM; VITAMIN DEFICIENCY;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CHOLINE DEFICIENCY; DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; HEPATOCYTES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; RECEPTORS, THYROID HORMONE; TRIIODOTHYRONINE;

EID: 65449134288     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22750     Document Type: Article

References (48)

1. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007;213:286-300.
2. Craddock VM. Cell proliferation and experimental liver cancer. In: Cameron HN, Linsell DA, Warwick GP, eds. Liver Cell Cancer. Amsterdam: Elsevier/North Holland Biochemical Press. 1976:153-201.
3. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-7421.
4. Trichopoulos D, Lipworth L, Petridou E, Adami HO. Epidemiology of cancer. In: De Vita VT, Helmann S, Rosenberg SA, editors. Cancer: Principles and Practise of Oncology. Philadelphia: Lippincott-Raven Publishers, 1997:231-257.
5. Bonkovsky HL, Ponka P, Bacon BR, Drysdale J, Grace ND, Tavill AS. An update on iron metabolism: Summary of the Fifth International Conference on Disorders of Iron Metabolism. HEPATOLOGY1996;24: 718-729.
6. Kew MC. Hepatocellular cancer. A century of progress. Clin liver Dis 2000;4:257-268.
7. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, et al. p53 mutations, chronic hepatitis B virus infection, and aflotoxin exposure in hapatocellular carcinoma in Taiwan. Cancer Res 1997;15:3471-3477.
8. Ames BN, Gold LS. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 1990;249:970-971.
9. Weinstein BI. Mitogenesis is only one factor in carcinogenesis. Science 1991;5:387-388.
10. Francavilla A, Carr BI, Azzarone A, Polimeno L, Wang Z, Van Diehl DH, et al. Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro. HEPATOLOGY 1994;20:1237-1241.
11. Pibiri M, Ledda-Columbano GM, Cossu C, Simbula G, Menegazzi M, Shinozuka H, et al. Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3). FASEB J 2001;15:1006-1013.
12. Ledda-Columbano GM, Perra A, Loi R, Shinozuka H, Columbano A. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer Res 2000;60:603-609.
13. Ledda-Columbano GM, Perra A, Concas D, Cossu C, Molotzu F, Sartori C, et al. Different effects of the liver mitogens triiodo-thyronine and ciprofibrate on the development of rat hepatocellular carcinoma. Toxicol Pathol 2003;31:113-120.
14. Shinozuka H, Katyal SL. Pathology of choline deficiency. In: Sidransky H, editor. Nutritional Pathology. New York: Marcel Dekker, 1985:279-320.
15. Takahashi S, Lombardi B, Shinozuka H. Progression of carcinogen-induced foci of gamma-glutamyltranspeptidase-positive hepatocytes to hepatoma in rats fed a choline-deficient diet. Int J Cancer 1982;29:445-450.
16. Reddy JK, Rao SR. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointestinal Liver Physiol 2005;GI290:852-858.
17. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-509.
18. Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RCJ, Scanlan TS. A high affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 1998;5:299-306.
19. Shinozuka H, Lombardi B, Sell S, Iammarino RM. Early histological and functional alterations of ethionine liver carcinogenesis in rats fed a choline deficient diet. Cancer Res 1978;38:1092-1098.
20. Solt DB, Farber E. New principle for the analysis of chemical carcinogenesis. Nature 1976;263:702-703.
21. Rutenburg AN, Kin H, Fishbein JW, Hanker JS, Wasserburg HL, Seligman AM. Histochemical and ultrastructural demonstration of gamma-glutamyl transpeptidase activity. J Histochem Cytochem 1969;17:517-526.
22. Wachstein M, Meisel E. Histochemistry of hepatic phosphatase at a physiological PH. Am J Clin Pathol 1957;27:13-23.
23. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International 2004;11:36-42.
24. Perra A, Simbula G, Simbula M, Pibiri M, Kowalik MA, Sulas P, et al. Thyroid hormone (T3) and Trβ agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J 2008;22:2981-2989.
25. Pitot HC, Dragan Y, Sargent L, Xu Y-H. Biochemical markers associated with the stages of promotion and progression during hepatocarcinogenesis in the rat. Environ Health Persp 1991;93:181-189.
26. RoomiMW,Ho RK, Sarma DS, Farber E. A common biochemical pattern in preneoplastic hepatocyte nodules generated in four different models in the rat. Cancer Res 1985;45:564-5671.
27. Satoh K, Kitahara A, Soma Y, Hatayama I, Sato K. Purification, induction, and distribution of placental glutathione transferase: A new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc Natl Acad Sci U S A 1985;82:3964-3968.
28. Tsuda H, Moore MA, Asamoto M, Inoue T, Ito N, Satoh K, et al. Effect of modifying agents on the phenotypic expression of cytochrome P-450, glutathione S-transferase molecular forms, microsomal epoxide hydrolase, glucose-6-phosphate dehydrogenase and gamma-glutamyltranspeptidase in rat liver preneoplastic lesions. Carcinogenesis 1988;9:547-554.
29. Enomoto K, Farber E. Kinetics of phenotypic maturation of remodeling of hyperplastic nodules during liver carcinogenesis. Cancer Res 1982;42: 2330-2335.
30. Moore MA, Hacker HJ, Bannasch P. Phenotypic instability in focal and nodular lesions induced in a short term system in the rat liver. Carcinogenesis 1983;4:595-603.
31. Stinchcombe S, Buchmann A, Bock KW, Schwarz M. Inhibition of apoptosis during 2,3,7,8-tetrachloro-p-dioxin-mediated tumour promotion in rat liver. Carcinogenesis 1995;16:1271-1275.
32. Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984;5:453-458.
33. Garcea R, Daino L, Pascale R, Simile MM, Puddu M, Frassetto S, et al. Inhibition of promotion and persistent nodule growth by S-adenosyl-Lmethionine in rat liver carcinogenesis: Role of remodeling and apoptosis. Cancer Res 1989;49:1850-1856.
34. Grausl-Kraupp B, Bursch W, Ruttkay Nedecky B, Wagner A, Lauer F, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci U S A 1994;91:9995-9999.
35. Rao MS, Reddy JK. An overview of peroxisome proliferator-induced hepatocarcinogenesis. Environ Health Perspect 1991;93:205-209.
36. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001;81:1097-1142.
37. Brent GA. The molecular basis of thyroid hormone action. New Engl J Med 1994;331:847-853.
38. Sporn MB, Roberts AB, Goodman DS. The Retinoids: Biology, Chemistry, and Medicine. New York: Raven Press, 1994.
39. De Luca LM. Retinoid and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991;5:2924-2933.
40. Columbano A, Shinozuka H. Liver regeneration versus direct hyperplasia. FASEB J 1996;10:1118-1128.
41. Ledda-Columbano GM, Pibiri M, Molotzu F, Cossu C, Sanna L, Simbula G, et al. Induction of hepatocyte proliferation by retinoic acid. Carcinogenesis 2004;25:2061-2066.
42. Ledda-Columbano GM, Curto M, Piga R, Zedda AI, Menegazzi M, Sartori C, et al. In vivo hepatocyte proliferation is inducible through a TNF and IL-6-independent pathway. Oncogene 1998;17:1039-1044.
43. Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 2000;32:187-204.
44. Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M, et al. Loss of Trim24 (Tif1a) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genetics 2007;39:1500-1506.
45. Hayashi M, Tamura T, Kuroda J, Ohnota H, Shibata N, Akahane M, et al. Effects in the early and late phase of treatment with KAT-681, a liver selective thyromimetic, on rat hepatocarcinogenesis induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Toxicol Sci 2005;84:22-28.
46. Lin KH, Wu YH, Chen SL. Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators. Endocrinology 2001;142:653-662.
47. Lin KH, Zhu XG, Hsu HC, Chen SL, Shieh HY, Chen ST, et al. Dominant negative activity of mutant thyroid hormone α1 receptors from patients with hepatocellular carcinoma. Endocrinology 1997;138:5308-5315.
48. Barlow C, Meister B, Lardelli M, Lendahl U, Vennstrom B. Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v- erbA. EMBO J 1994;13:4241-4250.